WVT078 + WHG626

WVT078 + WHG626 is an investigational **combination therapy** for relapsed and/or refractory multiple myeloma. WVT078 is a bispecific monoclonal antibody (BsAb) that targets B-cell maturation antigen (**BCMA**) on multiple myeloma cells and **CD3** on T cells, thereby redirecting T cells to kill myeloma cells. WHG626 (AL102) is a **gamma-secretase inhibitor (GSI)** that prevents cleavage and shedding of BCMA from the tumor cell surface, increasing the amount of targetable BCMA available for WVT078 and consequently enhancing T-cell engagement. The combination is being evaluated in phase 1 clinical trials, with evidence that the addition of WHG626 may enhance efficacy and T-cell activation, allowing for effective responses at lower WVT078 doses than as a single agent. The combination is given as intravenous WVT078 (12–48 µg/kg weekly) and oral WHG626 (2–4 mg daily, 2 days on/5 days off). Early data suggest an acceptable and manageable safety profile consistent with known effects of each agent, with common adverse events including cytokine release syndrome, pyrexia, diarrhea, and cytopenias[1][3][4].